Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Sell
50
CAPR Quote, Financials, Valuation and Earnings
Last price:
$14.07
Seasonality move
:
42.43%
Day range:
$13.61 - $14.30
52-week range:
$3.52 - $23.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
19.15x
P/B ratio:
9.33x
Volume:
333.8K
Avg. volume:
1.6M
1-year change:
214.83%
Market cap:
$637M
Revenue:
$25.2M
EPS (TTM):
-$1.02
Analysts' Opinion
-
Consensus RatingCapricor Therapeutics has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Capricor Therapeutics has an estimated upside of 194.69% from its current price of $14.01.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $14.01.
Fair Value
-
According to the consensus of 0 analysts, Capricor Therapeutics has 194.69% upside to fair value with a price target of -- per share.
CAPR vs. S&P 500
-
Over the past 5 trading days, Capricor Therapeutics has overperformed the S&P 500 by 3.1% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Capricor Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Capricor Therapeutics revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Capricor Therapeutics reported revenues of $2.3M.
Earnings Growth
-
Capricor Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Capricor Therapeutics reported earnings per share of -$0.38.
Enterprise value:
552M
EV / Invested capital:
8.09x
Price / LTM sales:
19.15x
EV / EBIT:
--
EV / Revenue:
23.76x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-14.40x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-61.67%
Net Income Margin (TTM):
-146.86%
Return On Equity:
-143.31%
Return On Invested Capital:
-143.31%
Operating Margin:
-575.24%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | $14M | $23.2M | $6.2M | $2.3M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$28M | -$30.9M | -$36.1M | -$6.9M | -$13M | |
| EBITDA | -$27.6M | -$29.9M | -$34.8M | -$6.6M | -$12.6M | |
| Diluted EPS | -$1.13 | -$1.16 | -$1.02 | -$0.25 | -$0.38 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $35.5M | $41.3M | $47.5M | $29.5M | $85.8M | |
| Total Assets | $36.2M | $43.1M | $53.9M | $37.2M | $93M | |
| Current Liabilities | $2.3M | $3M | $23.2M | $32.9M | $20.5M | |
| Total Liabilities | $5.8M | $6.4M | $38.5M | $38.9M | $24.7M | |
| Total Equity | $30.4M | $36.7M | $15.4M | -$1.8M | $68.3M | |
| Total Debt | $318.2K | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $6.2M | -$20.9M | -$36.8M | -$8.8M | -$11.6M | |
| Cash From Investing | -$40.6M | $16.1M | $1.3M | $7.7M | $2M | |
| Cash From Financing | $2M | $5.4M | $94.9M | $221.1K | $67.3M | |
| Free Cash Flow | $3.7M | -$23.4M | -$38.3M | -$9.4M | -$11.7M | |
CAPR
Sector
Market Cap
$637M
$46.1M
Price % of 52-Week High
59.87%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
-15.43%
-0.6%
1-Year Price Total Return
214.83%
-30.52%
Beta (5-Year)
3.980
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$13.37
200-day SMA
Buy
Level
$9.03
Bollinger Bands (100)
Buy
Level
5.89 - 19.29
Chaikin Money Flow
Sell
Level
-92.7M
20-day SMA
Sell
Level
$15.04
Relative Strength Index (RSI14)
Sell
Level
43.17
ADX Line
Buy
Level
19.93
Williams %R
Neutral
Level
-50.4225
50-day SMA
Sell
Level
$17.75
MACD (12, 26)
Sell
Level
-1.15
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Neutral
Level
488.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.7934)
Sell
CA Score
(Annual)
Level (-3.1235)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (4.2939)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.
Stock Forecast FAQ
In the current month, CAPR has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CAPR average analyst price target in the past 3 months is --.
-
Where Will Capricor Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Capricor Therapeutics share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Capricor Therapeutics?
Analysts are divided on their view about Capricor Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Capricor Therapeutics is a Sell and believe this share price will drop from its current level to --.
-
What Is Capricor Therapeutics's Price Target?
The price target for Capricor Therapeutics over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CAPR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Capricor Therapeutics is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of CAPR?
You can purchase shares of Capricor Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Capricor Therapeutics shares.
-
What Is The Capricor Therapeutics Share Price Today?
Capricor Therapeutics was last trading at $14.07 per share. This represents the most recent stock quote for Capricor Therapeutics. Yesterday, Capricor Therapeutics closed at $14.01 per share.
-
How To Buy Capricor Therapeutics Stock Online?
In order to purchase Capricor Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
60
QMCO alert for Dec 26
Quantum [QMCO] is up 49.62% over the past day.
Buy
53
ARQQ alert for Dec 26
Arqit Quantum [ARQQ] is up 49.85% over the past day.
Buy
65
TSLL alert for Dec 26
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 3.73% over the past day.
